TY - JOUR T1 - [Drug treatment of migraine attacks. Pharmacological considerations]. A1 - Salvesen,R, PY - 1996/8/10/pubmed PY - 1996/8/10/medline PY - 1996/8/10/entrez SP - 2176 EP - 9 JF - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke JO - Tidsskr Nor Laegeforen VL - 116 IS - 18 N2 - In the 1990s, the Decade of the Brain, significant progress has been made in our understanding of the pathophysiological events that take place during a migraine attack. Simultaneously, a big step forward has been made as regards drug therapy. The development of the 5-Hydroxy Tryptamine ID (5HT1D)-agonist sumatriptan has changed the lives of many migraine sufferers. This review describes attack management with analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), ergotamines and sumatriptan. Adverse events associated with ergotamines and use of sumatriptan are focused upon, with special attention to the pharmacokinetic and pharmacodynamic aspects of both these drugs. Sumatriptan has both vascular and neurogenic effects, both of which may be necessary for a good clinical outcome. SN - 0029-2001 UR - https://www.unboundmedicine.com/medline/citation/8801661/[Drug_treatment_of_migraine_attacks__Pharmacological_considerations]_ L2 - http://www.diseaseinfosearch.org/result/4811 DB - PRIME DP - Unbound Medicine ER -